Please assess the completion status of the following clinical trial:

Trial Title: The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or older at time of study entry~2. Willing and able to give informed consent~3. Diagnosed with CML in chronic phase and have either the b3a2 (e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR-ABL protein~4. Currently taking imatinib, dasatinib, nilotinib or bosutinib~5. Patient has been on TKI therapy for at least 3 years~6. Documented BCR-ABL \<0.01% (\>MR4 i.e. \>4 log reduction) or undetectable BCR-ABL by PCR for at least 2 years according to the patient's local lab~7. Documented BCR-ABL \<0.01% (\>MR4 i.e. \>4 log reduction) or undetectable BCR-ABL at least 3 times prior to screening according to the patient's local lab~8. Two (2) Screening PCRs have been completed and both results are \< 0.01% (\>MR4 i.e \> 4 log reduction) by central lab~9. Has been on any number of TKIs, but has not been resistant to any TKI (changes made for intolerance are allowed)~10. Patient has been compliant with therapy per treating physician~Exclusion Criteria:~1. Prior hematopoietic stem cell transplantation~2. Poor compliance with taking TKI~3. Unable to comply with lab appointments schedule and PRO assessments~4. Life expectancy less than 36 months~5. Patients who have been resistant to previous TKI therapy are not eligible~6. Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Discontinuation of TKI medication (Type: OTHER): Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years.

Based on this trial design, predict the completion outcome and termination type (if applicable).